Iovance Bio updates cervical cancer program data post FDA meeting

The innovaTIL-04 study is anticipated to register a total of 75 to 100 patients with the aim to support a BLA submission

Reports confirm that Iovance Biotherapeutics, Inc., a biotech company, has recently provided update regarding the regulatory path for LN-145 in advanced cervical cancer program, following the End of Phase 2 meeting conducted with the U.S. Food and Drug Administration.

Apparently, the FDA has acknowledged that the current innovaTIL-04 study of LN-145, a TIL treatment, might be enough for supporting enrolment in the treatment of advanced cervical cancer patients. The study is being registered with a potential definition of objective response rate stated by a Blinded Independent Review Committee as the primary endpoint.

Sources mentioned that in accordance with the recommendation of FDA, the novel version of the protocol will further describe the patient population. In the Biologics License Application, Iovance formally plans to include patients who have advanced following initial systemic therapy for metastatic or recurrent disease, which accounts for almost overall more advanced patients registered till date.

Along with this, the company had announced that the innovaTIL-04 study is anticipated to register a total of 75 to 100 patients with the aim to support a BLA submission.

According to Chief Executive Officer and President of Iovance Biotherapeutics, Maria Fardis, Ph.D., the agreement with FDA is to consider acceptability of the existing trial in patients suffering with cervical cancer considerably accelerates the way to BLA submission for LN-145. The capability to use the existing study, as well as the Breakthrough Therapy label recently granted to LN-145, enables the company to plan a route to submitting BLA in the second half of 2020.

For the uninitiated, Iovance Biotherapeutics develops innovate cancer immunotherapies that are based on tumor-infiltrating lymphocyte technology. It aims to market autologous cell therapy portfolio that strengthens the immune response of the body itself to attack blood cancers or eliminate solid tumors. The company is presently performing the key study innovaTIL-01 in patients with metastatic melanoma.

Source Credit: http://ir.iovance.com/phoenix.zhtml?c=254507&p=irol-newsArticle&ID=2402832